Advanced

Animal Models of Parkinson's Disease: Limits and Relevance to Neuroprotection Studies

Bezard, Erwan ; Yue, Zhenyu ; Kirik, Deniz LU and Spillantini, Maria Grazia (2013) In Movement Disorders 28(1). p.61-70
Abstract
Over the last two decades, significant strides has been made toward acquiring a better knowledge of both the etiology and pathogenesis of Parkinson's disease (PD). Experimental models are of paramount importance to obtain greater insights into the pathogenesis of the disease. Thus far, neurotoxin-based animal models have been the most popular tools employed to produce selective neuronal death in both in vitro and in vivo systems. These models have been commonly referred to as the pathogenic models. The current trend in modeling PD revolves around what can be called the disease gene-based models or etiologic models. The value of utilizing multiple models with a different mechanism of insult rests on the premise that dopamine-producing... (More)
Over the last two decades, significant strides has been made toward acquiring a better knowledge of both the etiology and pathogenesis of Parkinson's disease (PD). Experimental models are of paramount importance to obtain greater insights into the pathogenesis of the disease. Thus far, neurotoxin-based animal models have been the most popular tools employed to produce selective neuronal death in both in vitro and in vivo systems. These models have been commonly referred to as the pathogenic models. The current trend in modeling PD revolves around what can be called the disease gene-based models or etiologic models. The value of utilizing multiple models with a different mechanism of insult rests on the premise that dopamine-producing neurons die by stereotyped cascades that can be activated by a range of insults, from neurotoxins to downregulation and overexpression of disease-related genes. In this position article, we present the relevance of both pathogenic and etiologic models as well as the concept of clinically relevant designs that, we argue, should be utilized in the preclinical development phase of new neuroprotective therapies before embarking into clinical trials. (C) 2012 Movement Disorder Society (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
6-OHDA, MPTP, alpha-synuclein, LRRK2, neurodegeneration, dopamine, viral, vectors
in
Movement Disorders
volume
28
issue
1
pages
61 - 70
publisher
John Wiley and Sons Inc.
external identifiers
  • wos:000314995300009
  • scopus:84873476695
  • pmid:22753348
ISSN
0885-3185
DOI
10.1002/mds.25108
language
English
LU publication?
yes
id
df0100ce-2597-44cd-b088-4656f2cbeab4 (old id 3589829)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22753348
date added to LUP
2016-04-01 10:00:32
date last changed
2020-09-16 01:07:59
@article{df0100ce-2597-44cd-b088-4656f2cbeab4,
  abstract     = {Over the last two decades, significant strides has been made toward acquiring a better knowledge of both the etiology and pathogenesis of Parkinson's disease (PD). Experimental models are of paramount importance to obtain greater insights into the pathogenesis of the disease. Thus far, neurotoxin-based animal models have been the most popular tools employed to produce selective neuronal death in both in vitro and in vivo systems. These models have been commonly referred to as the pathogenic models. The current trend in modeling PD revolves around what can be called the disease gene-based models or etiologic models. The value of utilizing multiple models with a different mechanism of insult rests on the premise that dopamine-producing neurons die by stereotyped cascades that can be activated by a range of insults, from neurotoxins to downregulation and overexpression of disease-related genes. In this position article, we present the relevance of both pathogenic and etiologic models as well as the concept of clinically relevant designs that, we argue, should be utilized in the preclinical development phase of new neuroprotective therapies before embarking into clinical trials. (C) 2012 Movement Disorder Society},
  author       = {Bezard, Erwan and Yue, Zhenyu and Kirik, Deniz and Spillantini, Maria Grazia},
  issn         = {0885-3185},
  language     = {eng},
  number       = {1},
  pages        = {61--70},
  publisher    = {John Wiley and Sons Inc.},
  series       = {Movement Disorders},
  title        = {Animal Models of Parkinson's Disease: Limits and Relevance to Neuroprotection Studies},
  url          = {http://dx.doi.org/10.1002/mds.25108},
  doi          = {10.1002/mds.25108},
  volume       = {28},
  year         = {2013},
}